Johnson & Johnson (JNJ) just got some relief in a billion-dollar legal mess, though calling it a win might be generous. Delaware's Supreme Court on Monday overturned part of a massive damages award tied to J&J's troubled acquisition of Auris Health, a surgical robotics company that J&J bought in 2019 for $3.4 billion cash, plus potential earnout payments worth another $2.35 billion.

The unanimous ruling from Delaware's top court set aside a chunk of the September 2024 judgment that favored former Auris shareholders. But before J&J breaks out the champagne, most of the lower court's findings remain intact, meaning the healthcare giant is still on the hook for substantial damages.

The Backstory: When Acquisitions Go Wrong

Here's what happened. J&J was desperately trying to build its own surgical robot called Verb, but the project was behind schedule and eating through cash. Surgical robotics represented a strategically critical market, and J&J needed a solution fast. Enter Auris Health and its iPlatform technology.

Auris agreed to the deal after securing J&J's commitment to treat its technology with "commercially reasonable efforts" consistent with a "priority medical device." Basically, Auris wanted assurance that J&J wouldn't acquire them just to shelve their tech.

Spoiler alert: that's essentially what happened. After the acquisition closed, J&J allegedly failed to honor its commitment. Instead of supporting iPlatform's regulatory progress toward FDA approval, J&J forced it into direct competition with its struggling Verb robot under something called "Project Manhattan." This halted regulatory momentum and diverted engineering resources away from getting iPlatform approved.

The irony? iPlatform ultimately outperformed Verb. But rather than admit defeat, J&J merged the two programs in a way that effectively subordinated iPlatform to salvage its Verb investment.

The Legal Battle

Former Auris shareholders weren't having it. They sued for breach of contract, breach of the implied covenant of good faith and fair dealing, and fraud.

In 2024, the Chancery Court sided with them, finding that Johnson & Johnson breached its obligations by failing to prioritize iPlatform, undermining regulatory milestones, and acting specifically to avoid paying the earnout. The court also found J&J breached the implied covenant by refusing to support a revised regulatory pathway. Separately, J&J was nailed for fraud by failing to disclose a regulatory investigation tied to a Monarch milestone that J&J had represented as virtually guaranteed.

Total damages, including interest, exceeded $1 billion—compensating Auris shareholders for the earnout payments they would have received if J&J had kept its promises.

The Supreme Court's Ruling

Now comes the partial reversal. Justice Abigail LeGrow rejected one key finding from the lower court. She ruled that the Chancery Court erred in concluding J&J had an implied obligation to secure regulatory approval by the end of 2021 for an iPlatform product related to abdominal procedures. The Supreme Court said the merger agreement's language simply didn't support that specific requirement.

Despite that reversal, the justices upheld most of Vice Chancellor Lori Will's findings, leaving intact the conclusions that J&J failed to meet other contractual obligations. The case now heads back to Will's court for damage recalculation.

What Happens Next

J&J says it's reviewing its options, which is corporate-speak for "our lawyers are figuring out what to do." The damage recalculation could reduce the total award by a couple hundred million dollars, which sounds like a lot until you remember we're starting from over $1 billion.

This isn't J&J's only legal headache. In December 2025, a Baltimore jury ordered Johnson & Johnson and its subsidiaries to pay over $1.5 billion to a woman who claimed decades of exposure to asbestos in the company's talc-based products caused her peritoneal mesothelioma.

Johnson & Johnson shares were up 0.46% at $210.68 at the time of publication on Tuesday, approaching the stock's 52-week high of $215.18. Apparently investors are taking the partial legal win as good news, or at least not-as-bad-as-it-could-have-been news.